<unk>  does not improve mortality in severe sepsis or septic shock but does increase bleeding risks. Therefore, a 2012 Cochrane review recommended that clinicians and policymakers not recommend its use and Eli Lilly has announced the discontinuation of all clinical trials.
Drotrecogin alfa
Efmoroctocog alfa
Vonicog alfa
Etelcalcetide
Susoctocog alfa
Moroctocog alfa
Sulfatide
Velmanase alfa